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Abstract
Background: Mechanisms underlying the malignant development in bladder cancer are still not
well understood. Lipolysis stimulated lipoprotein receptor (LSR) has previously been found to be
upregulated by P53. Furthermore, we have previously found LSR to be differentially expressed in
bladder cancer. Here we investigated the role of LSR in bladder cancer.
Methods: A time course siRNA knock down experiment was performed to investigate the
functional role of LSR in SW780 bladder cancer cells. Since LSR was previously shown to be
regulated by P53, siRNA against TP53 was included in the experimental setup. We used Affymetrix
GeneChips for measuring gene expression changes and we used Ingenuity Pathway Analysis to
investigate the relationship among differentially expressed genes upon siRNA knockdown.
Results: By Ingenuity Pathway analysis of the microarray data from the different timepoints we
identified six gene networks containing genes mainly related to the functional categories "cancer",
"cell death", and "cellular movement". We determined that genes annotated to the functional
category "cellular movement" including "invasion" and "cell motility" were highly significantly
overrepresented. A matrigel assay showed that 24 h after transfection the invasion capacity was
significantly increased 3-fold (p < 0.02) in LSR-siRNA transfected cells, and 2.7-fold (p < 0.02) in
TP53-siRNA transfected cells compared to controls. After 48 h the motility capacity was
significantly increased 3.5-fold (p < 0.004) in LSR-siRNA transfected cells, and 4.7-fold (p < 0.002)
in TP53-siRNA transfected cells compared to controls.
Conclusion:  We conclude that LSR may impair bladder cancer cells from gaining invasive
properties.
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Background
Completion of the human genome project [1,2] together
with development of microarray techniques have made it
possible to investigate global changes in expression pat-
terns that occur during bladder cancer development. Gene
expression profiles associated with disease stage [3-7], dis-
ease progression [4,7,8], recurrence pattern [4], survival
[6,9], and treatment response [10] have been delineated
by several groups. Other studies have focused on the
impact of single genes on tumorigenesis like the onco-
genes HRAS, FGFR3, ERBB2, CCND1, and MDM2, and the
tumor suppressors CDKN2A,  PTEN,  TSC1, and DBC1
(recently reviewed in [11]). Thus, knowledge on molecu-
lar alterations of single parameters is available, but the
complex network of molecular events leading to invasive
bladder cancer still requires further attention.
In this study we have focused on the lipolysis stimulated
lipoprotein receptor gene (LSR), which is differentially
expressed in bladder cancer. LSR was identified in 1992 as
a receptor distinct from the low density lipoprotein recep-
tor (LDLR) and low density lipoprotein-related protein 1
(LRP1) [12,13]. LSR binds ApoB and ApoE containing
lipoproteins, especially chylomicrons and VLDL [12-15].
Unsaturated, long-chained (>12C) free fatty acids like
oleate activate the receptor by causing a conformational
change that expose the binding site [12-14,16]. The appar-
ent number of LSR binding sites expressed at the surface
of hepatocytes correlates negatively with plasma triglycer-
ide levels measures at the postprandial stage [14]. After
binding to LSR, the ligands are internalised and proteo-
lytic degraded in lysosomes [12,13]. LSR binding is inhib-
ited by lactoferrin [12-14], receptor associated protein
(RAP) [17], and apoC-III [18], which all are reported to
have hyperlipidemic effects. Previously, in an effort to
identify primary TP53 targets, LSR was found to be upreg-
ulated by TP53 [19]. In another study, LSR was downreg-
ulated more than 2 fold upon TGF-β1 stimulation in wild-
type cells with an active Smad4-TGF-β signalling pathway
[20].
Here we investigated the participation of LSR in SW780
bladder cancer cells motility and invasion. We used a
siRNA knock down in vitro assay where LSR and TP53
were knocked down individually and in combination in
SW780 bladder cancer cells. Time course microarray anal-
yses were used to measure the global consequences of the
knockdown. In silico prediction of LSR regulated motility
and invasion was experimentally verified by a matrigel
assay.
Methods
Antibody synthesis
Polyclonal rabbit anti-LSR antibodies were raised against
the peptide
[C]VTSLHEDDWRSRPSR, aa 386–400, BC000015.2
6.6.2006) conjugated to the carrier protein KLH (Keyhole
limpet hemocyanin) (Eurogentec, Belgium). CLUSTALW
analysis matched the peptide sequence to all three iso-
forms I1 NP_057009.3 (630 aa), I2 NP_991403.1 (649
aa) and I3 NP_991404.1 (581 aa) as shown in Additional
File 1.
Cloning and overexpression
cDNA was synthesized from total RNA from stage Ta
tumors (non muscle invasive tumors) using Super-
scriptTM cDNA synthesis kit (Invitrogen). cDNA was PCR
amplified using primers sense 5'-ATGCAACAGGACG-
GACTTGG and antisense 3'-AGTCGGGAAAGTT-
TAGTCGTCTGA. The LSR PCR product was cloned into
pcDNA 3.1 bidirectional (Invitrogen). Transient transfec-
tion with pcDNA 3.1_LSR isoform 1 and pcDNA 3.1_LSR
isoform 3 of COS7 cells was achieved using FuGene
(Roche) following the manufacturer's instructions yield-
ing fragments with a 48 aa N-terminal truncation.
Cell extraction, SDS gels and Western blots
COS7 cells transfected with pcDNA 3.1_LSR isoform 1 or
isoform 3 were harvested by scraping and lysed in lysis
buffer (50 mM Tris.HCl pH 8.0, 150 mM NaCl, 1 mM
DTT, 1% Triton X-100, protease inhibitor Roche com-
plete, EDTA free). 10–20 μg total protein samples were
run in 12% SDS gels (Invitrogen) and transferred to PVDF
membranes. Membranes were blocked with 3% w/v non-
fat powder milk in PBS. The primary antibody was rabbit
polyclonal anti-LSR (1:6000) and the secondary antibody
goat anti-rabbit HRP conjugated (1:5000), DakoCytoma-
tion. The immunoreactive bands were visualised using
ECL plus (Amersham biosciences) and an UVP Chemi-
Doc-It, Imaging system, UVP Inc.
Immunohistochemistry
Immunohistochemistry was performed using 4 μm for-
malin fixed paraffin embedded (FFPE) sections of histo-
logical specimens as described previously [21]. We used a
1:3500 dilution of the rabbit polyclonal anti human LSR-
antibody. Staining was scored independently by two
observers (L.D and M.H). Staining categories were defined
as no, weak, moderate or strong staining. In case of disa-
greement, the samples were re-evaluated and a consensus
scoring was achieved.
Knock down assay
SW780 cells (ATCC, CRL-2169) were grown in D-MEM
medium (Invitrogen, cat. no. 31885-023) supplemented
with 10% FCS (Invitrogen, cat.no. 10270-106) and 1%
penicillin/streptomycin (Invitrogen, cat. no. 15140-122)
at 37°C in a humidified environment with 5% CO2
atmosphere. The SW780 cells were selected for this study
because they originate from a grade 1 tumor and henceBMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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resemble early steps in carcinogenesis before the cells
become invasive. Cells were tested negative for Myco-
plasma infection by MycoSensor PCR Assay set (Strata-
gene, cat. no. 302108, La Jolla, CA.).
Cells were harvested with Trypsin (cat.no. 25300-062). A
nucleofector (Amaxa, Cologne, Germany) was used for
cell transfections using Amaxa's standard program A23
[22]. For each siRNA construct 0.8 × 106 cells resuspended
in 100 μl solution R (standard solution) were transiently
transfected with a total of 1.2 μg siRNA using either mock
siRNA (Non-targeting siRNA, Dharmacon, cat. no. D-
001210-01), TP53 siRNA (Dharmacon, cat. no. M-
003329-00), first LSR siRNA (LSR1, UCA AAG GUC AGG
UCA GCA UTT, DNA Technology), second LSR siRNA
(LSR2, siRNA ID 116788, Ambion), or 0.6 μg TP53 siRNA
plus 0.6 μg LSR1. Transfected cells were grown for 18 h
(one sample per siRNA construct), 48 h (4 samples per
construct) or 72 h (one sample split in two technical rep-
licates for further analysis).
Cells were harvested by scraping the flasks with 1 ml lysis
buffer and total RNA was extracted from the cells using
GenElute Mammalian Total RNA Miniprep Kit (Sigma-
Aldrich, St. Louis, MO, cat.no. RTN350) according to the
manufacturer's instructions.
Microarray analysis of cell lines
Double stranded cDNA synthesis, in vitro transcription
and labelling of cRNA, hybridisation and scanning was
performed using standard procedures, see reference [5]. A
total of thirty-five HG-U133 Plus 2 GeneChips (Affyme-
trix) were used.
Data analysis of cell line microarray data
The arrays were normalised and expression measures gen-
erated using the GCRMA method [23] implemented in
the ArrayAssist software (Stratagene). GCRMA stands for
GeneChip robust multi-array analysis – see reference
[22,24]. The mean expression of TP53 and LSR was calcu-
lated for each transfection and time point using the
probes for LSR (208190_s_at) and TP53 (201746_at).
There are two probesets for TP53 on the HG-U133 Plus 2
GeneChip, however, the other probeset (211300_s_at) is
not specific for TP53. Then, for each time point three fil-
ters were applied to identify differentially expressed genes.
The first filter removed non-expressed transcripts, in the
way that transcripts were kept if all replicate samples from
at least one siRNA construct were at least 6 (log2 scale
number). The second filter was applied for each knock-
down experiment (TP53, LSR1, LSR2, LSR1+TP53). It
included transcripts, where the mean expression of mock
transfected cells or the mean expression of knock down
transfected cells was at least 6. An expression above 6 was
defined as being above the noise threshold. Using these
filters for the three time points gave twelve different sub-
sets of probes with approximately 16,000 transcripts. A
third filter was applied in Ingenuity, where a cut-off was
applied to define "Focus Genes" as genes with a mean log
ratio (compared to mock) of ≥ |1|. We used Excel (Micro-
soft) for filtering the data.
Bioinformatics using Ingenuity Pathway Analysis
Each probe was mapped to its corresponding gene object
in the Ingenuity Pathways Knowledge Base (IPKB). "Focus
Genes" were superimposed the global molecular network
developed from information contained in the IPKB.
"Local networks" preferentially enriched of these Focus
Genes were then generated based on their connectivity.
The "Functional Analysis of a network" identified the bio-
logical functions and/or diseases that were most signifi-
cant to the genes in the network. The network genes
associated with biological functions and/or diseases in the
IPKB were considered for the analysis. Fischer's exact test
was used to calculate a p-value determining the probabil-
ity that each biological function and/or disease assigned
to that network is due to chance alone.
The "Global Functional Analysis" identified the biological
functions and/or diseases that were most significant to the
entire data set. Genes from the dataset that met the log
ratio cutoff of ≥ |1| and were associated with biological
functions and/or diseases in the IPKB were considered for
the analysis.
Microarray data from human tissue samples
We used an independent dataset previously generated
using HG-U133A Affymetrix GeneChips [5] on 87 blad-
der carcinomas (55 Ta tumors, 3 T1 tumors, and 29 T2–4
tumors) and 9 samples of normal urothelium. Gene
expression measures were generated and data normalized
using the GCRMA method [23] implemented in the Arra-
yAssist software (Stratagene). Mean expressions and log
ratios were calculated for tumor and normal samples. A
cut-off of log ratio ≥ |1| and p-value ≤ 0.05 was used to
define "focus genes" in the network analysis.
Realtime PCR
We measured expression of LSR (Assay ID
Hs00210880_m1), EMP3 (assay ID Hs00171319_m1),
AGR2 (assay ID Hs00180702_m1), CTGF (assay ID
Hs00170014_m1) and GAPDH (Assay ID
Hs99999905_m1) using standard procedures (Applied
Biosystems). All samples were amplified in triplicate in an
ABI Prism 7000 Thermal Cycler according to instructions
of the manufacturer. TP53 expression was measured using
a standard SYBR Green assay.BMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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Cell invasion assay
BD BioCoat Matrigel Invasion Chambers (BD Biosciences,
cat. no. 354480) were used. To measure motility and inva-
sion an equal number of control inserts (motility) and
matrigel inserts (invasion) were used. 0.8 × 106 cells were
transfected with AMAXA program A23 with 1.2 μg siRNA
in 100 μl AMAXA solution R (standard solution in the
Amaxa system) according to the instructions of the manu-
facturer. 25,000 transfected cells in a total volume of 0.5
ml were seeded into the top well of the inserts in serum
free medium. The lower well was filled with 750 μl
medium with serum. The transfected cells were allowed to
grow and invade for 24 h and 48 h. We chose the 24 h
timepoint instead of the 18 h timepoint that was used for
the microarray analysis in order allow an effect of siRNA
knockdown on the protein level. Then the non-invading
cells were scraped from the upper surface of the mem-
brane and the cells on the lower side were stained with
Hemacolor staining set (Merck, cat. no. 1.11674) and four
images covering the membrane were immediately taken
under microscope. Each siRNA construct was tested in
triplicate in both control inserts and matrigel inserts and
the mean number of invading cells was calculated.
Cell viability assay
A MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) ELISA assay (Roche, cat. no. 1-465-007)
was used to test the impact of LSR and TP53 knockdown
on cell viability. 0.8 × 106 SW780 cells were transfected
with AMAXA program A23 with 1.2 μg siRNA in 100 μl
AMAXA solution R for each siRNA construct. Cells were
grown in quadruplicate in 96-wells microtiter plates with
12.000 cells per well in a total volume of 100 μl medium.
After 24 h, 48 h or 72 h 10 μl MTT was added to a final
conc. 0.5 mg/ml and cells were allowed to incubate for
four hours. 100 μl solubilization solution was added to
each well and the cells were lysed during incubation over-
night. The absorbance was measured at 540 nm and 690
nm on a ELISA reader.
Results
Cloning and overexpression of LSR
From the data generated in a previous microarray screen-
ing of bladder tumors [5] we identified LSR as an interest-
ing candidate gene for further analysis. Therefore,
polyclonal rabbit anti-LSR antibodies were raised to char-
acterise LSR protein expression. PCR amplification identi-
fied two transcript isoforms present in human bladder
cancer, variants 1 and 3, while variant 2 was not ampli-
fied. Incubation of COS7 extracts overexpressing N-termi-
nal truncated proteins of variant 1 or variant 3 showed
that the antibody identified two LSR protein variants of
about 65 kDa and 59 kDa (Figure 1) with a high specifi-
city.
Expression of LSR protein in bladder tumors
Immunohistochemical analysis of FFPE tissue sections
from normal urothelium and bladder tumors showed a
moderate to strong cytoplasmic expression of LSR in
100% of normal samples and 70% of Ta tumors (Figure
2). The expression was observed in nearly all urothelial
cells. The overall number of cells staining positive for LSR
was significantly decreasing in T1 and T2–4 tumors (Ken-
dall's tau b, one-sided p-value = 0.0188), and only 38% of
the muscle invasive samples showed moderate to strong
cytoplasmic staining for LSR in the majority of cancer cells
(Additional File 2). No staining was detected in connec-
tive tissue or lymphocytes.
Microarray screening for LSR target genes
To investigate the function of LSR we used siRNA knock-
down in the bladder cancer cell line SW780, which
showed a high endogenous level of LSR expression.
SW780 was transiently transfected with siRNA and two
siRNAs against LSR were used (LSR1, LSR2) to evaluate
eventual off-target effects [25]. A possible relationship
between LSR and TP53 has been shown previously [19]
and therefore siRNA against TP53 was also included. LSR
was knocked down alone or in combination with TP53
(LSR1+TP53). All knock down experiments were com-
pared to cells transfected with a non-targeting siRNA
(mock).
Cells were harvested after 18 h, 48 h and 72 h and micro-
array data documented that mean LSR expression was
reduced significantly (Figure 3). Knockdown of TP53 tran-
scripts had no impact on LSR expression at any time
points. Measurements of TP53 expression showed that the
siRNA against TP53 reduced the TP53 transcript level to
10% (18 h), 16% (48 h), and 40% (72 h) compared to
Transient overexpression of truncated LSR isoforms 1 (v1)  and 3 (v3) in COS7 cells Figure 1
Transient overexpression of truncated LSR isoforms 
1 (v1) and 3 (v3) in COS7 cells. Cell extracts were west-
ern blotted and identified by staining with polyclonal rabbit 
antibody. Lane 1; Mol. weight markers,; lane 2, LSR isoform 
1; lane 3, LSR isoform 3.
97
68
45
1 2 3
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Immunohistochemical analysis of LSR expression in normal urothelium and bladder cancer samples Figure 2
Immunohistochemical analysis of LSR expression in normal urothelium and bladder cancer samples. The pro-
tein was located in the cytoplasm in >50% of the cancer cells. Original magnification, ×20 (all except C), ×10 (C). A: Normal 
bladder urothelium (21859-99); medium LSR expression. B: Negative control stain without primary antibody of T3 grade 3 
tumor (6268-96). C-D: Ta grade 2 bladder tumor (4232-97); median LSR expression. E: T1 grade 2 bladder tumor (6018-98); 
weak LSR expression. F: T1 grade 3 bladder tumor (5248-02); medium LSR expression. G: T3 grade 3 bladder tumor (6268-
96); weak LSR expression. H: T2 grade 3 bladder tumor (1719-00); weak, overall LSR expression in cytoplasm and nucleus.
Ó
Ó
ÑBMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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Transient transfection of SW780 bladder cancer cells with a non-targeting siRNA (Mock), two different siRNAs against LSR  (LSR1, LSR2), one siRNA against TP53 (TP53) and siRNA against LSR and TP53 in combination (LSR1+TP53) Figure 3
Transient transfection of SW780 bladder cancer cells with a non-targeting siRNA (Mock), two different siR-
NAs against LSR (LSR1, LSR2), one siRNA against TP53 (TP53) and siRNA against LSR and TP53 in combina-
tion (LSR1+TP53). Transfected cells were harvested 18 h (one sample per siRNA constructs), 48 h (4 samples per 
construct) or 72 h (one sample split in two technical replicates for further analysis) after transfection and gene expression was 
measured using microarray analysis (HG-U133 Plus 2 arrays, GeneChip, Affymetrix). The figure shows normalized mean 
expression of LSR (first graph column) and TP53 (second graph column). Error bars indicate +/- one standard deviation.BMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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mock transfected cells, while knockdown of LSR had no
effect on TP53 expression.
Overlapping effects of two LSR siRNAs
We found a large overlap in transcripts affected by LSR1
and LSR2, confirming that overall, the two LSR siRNAs
had similar effect (Additional File 3). Furthermore, tran-
scripts consistently affected over the three time points by
each of the two siRNAs showed considerable overlap
(Additional File 3); the sixteen common genes are shown
in Table 1. The majority (44%) of these genes encoded
proteins annotated to be located in the extracellular space
like CYR61.
Knockdown effects and QPCR verification
A large number of genes were found to be differentially
expressed upon knockdown (Additional File 4). 48 h after
transfection, the microarray analysis showed a significant
upregulation (1.6-fold, log2 scale) of the EMP3 expres-
sion (t-test, one-sided P = 9.9 × 10-6) and CTGF expression
(2.6 fold)(t-test, one-sided P = 5.6 × 10-5), while AGR2
expression was significantly downregulated (-1.5 fold) (t-
test, one-sided P = 1.3 × 10-5). QPCR analysis likewise
showed a significant differential regulation of the expres-
sion of EMP3 (t-test, P = 7.0 × 10-12), CTGF (t-test, P < 1.0
× 10-12), and AGR2 (t-test, one-sided P = 8.4 × 10-10). This
consistency was also found for the measurements 72 h
after transfection.
Bioinformatics analysis of the knockdown effects: Local 
network analysis
Using Ingenuity Pathway Analysis (IPA) we analysed the
relationship between genes with a changed expression
after knockdown of LSR, TP53 or both. "Local networks"
preferentially enriched for "focus genes" were generated
and ranked based on their connectivity (see Additional
File 5).
Down-regulation of TP53: We found that the highest
ranked local network upon downregulation of TP53 con-
tained 35 focus genes (Figure 4A), which were annotated
to the functional categories "cancer", "cellular growth and
proliferation", and "cell death" (p-values between 6.6E-13
– 4.1E-12).
Down-regulation of LSR: The highest ranked local net-
work was annotated to functional categories like "cell
growth and proliferation", "cell death", "cancer", and
"cellular movement" dominated (p-values between
2.72E-14 – 1.8E-8). The majority of the genes in these net-
works were up-regulated (Figure 5, 6). CYR61, EGR1, and
AKAP12, three of the genes constitutively regulated by
both LSR siRNAs, were included in these networks
(CYR61, Figure 5A and Figure 6A; EGR1, Figure 5B and
Figure 6B; AKAP12, Figure 6B).
Table 1: Consistently differentially expressed genes at all measurements after LSR knock down by both LSR siRNAs (log2 scale).
Location Gene LSR1 LSR2
18 h 48 h 72 h 18 h 48 h 72 h
Cytoplasm AKAP12 A kinase (PRKA) anchor protein (gravin) 12 1.2 1.8 1.9 1.1 2.1 2.1
Extracell. Space FST follistatin 1.8 3.2 2.8 1.9 3.9 3.6
APLP2 amyloid beta (A4) precursor-like protein 2 1.3 1.6 1.1 1.3 1.6 1.2
IL1A interleukin 1, alpha 1.3 2.0 1.7 1.4 2.1 2.2
CYR61 cysteine-rich, angiogenic inducer, 61 1.1 2.6 2.2 1.0 2.3 2.6
EDN1 endothelin 1 1.2 3.1 1.8 1.2 2.7 2.6
GLIPR1 GLI pathogenesis-related 1 (glioma) 1.4 2.2 2.6 1.7 2.8 2.8
PTHLH parathyroid hormone-like hormone 1.5 3.3 3.8 1.0 3.0 3.2
Nucleus EGR1 early growth response 1 2.0 3.7 2.5 2.9 1.6 3.5
MYOCD myocardin 1.1 1.9 2.1 1.1 1.5 1.8
Plasma Membrane TSPAN8 tetraspanin 8 -1.1 -1.9 -2.5 -1.9 -3.1 -3.0
MALL mal, T-cell differentiation protein-like 1.7 1.3 1.1 1.4 1.5 1.3
NEXN nexilin (F actin binding protein) 1.4 1.5 1.3 1.4 1.7 1.4
LSR lipolysis stimulated lipoprotein receptor -3.6 -2.8 -2.4 -2.6 -1.6 -1.3
Unknown TMCO1 transmembrane and coiled-coil domains 1 2.0 1.8 1.4 1.9 1.7 1.3
TRIM31 tripartite motif-containing 31 -1.3 -2.0 -1.5 -1.2 -1.9 -1.7
Genes in bold are known by the Ingenuity Pathway Knowledge Base. Figures indicate log2 fold change at various time points.BMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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Networks top-ranked by Ingenuity Pathway analysis after knockdown of TP53 (A) and LSR1+TP53 (B) Figure 4
Networks top-ranked by Ingenuity Pathway analysis after knockdown of TP53 (A) and LSR1+TP53 (B). Col-
oured genes are upregulated (yellow) or downregulated (blue) more than 2-fold. "Focus genes" (bold) were defined as genes 
with a mean log ratio of ≥ |1| compared to mock transfected cells. The horizontal lines separate different cellular compart-
ments.
A
BBMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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Networks top-ranked by Ingenuity Pathway analysis after knockdown of LSR1 (A-B) Figure 5
Networks top-ranked by Ingenuity Pathway analysis after knockdown of LSR1 (A-B). Coloured genes are upregu-
lated (yellow) or downregulated (blue) more than 2-fold. "Focus genes" (bold) were defined as genes with a mean log ratio of ≥ 
|1| compared to mock transfected cells. The horizontal lines separate different cellular compartments.
A
BBMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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Networks top-ranked by Ingenuity Pathway analysis after knockdown of LSR2 (A-B) Figure 6
Networks top-ranked by Ingenuity Pathway analysis after knockdown of LSR2 (A-B). Coloured genes are upregu-
lated (yellow) or downregulated (blue) more than 2-fold. "Focus genes" (bold) were defined as genes with a mean log ratio of ≥ 
|1| compared to mock transfected cells. The horizontal lines separate different cellular compartments.
A
BBMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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Down-regulation of TP53 and LSR in combination, 48 h:
The highest ranked local network upon downregulation
of TP53 and LSR contained 35 focus genes (Figure 4B).
These genes were annotated to the functional categories
"cancer", "cell death", and "cellular growth and prolifera-
tion" (p-values between 5.1E-11 – 6.0E-11).
Bioinformatics analysis of the knockdown effects: Global 
functional analysis
Using IPA a "global functional analysis" identified the
biological functions, processes or diseases that were most
relevant for the entire dataset.
Knockdown of TP53: We investigated the global func-
tional consequences of TP53 knockdown (Table 2). We
found, that 48 h after transfection the functions affected
were related to "cell-to-cell signalling" (P = 1.17 × 10-10),
"organism survival" (P = 1.74 × 10-9), and "cellular
growth and proliferation" (P = 1.29 × 10-8). The cell
death/survival effect was even more prominent 18 h after
transfection where all the three top-ranked functions were
related to "cell death and survival" (P = 5.96 × 10-9 – 3.72
× 10-8). This is consistent with the fact that TP53 expres-
sion was most prominent 18 h after transfection, where
the highest knockdown effect was observed.
Knockdown of LSR: We found that the three most signifi-
cant functions or processes after knockdown with LSR1
were all related to "cellular movements" (cell movement,
invasion of eukaryotic cells, and invasion of cell lines).
This was highly significant with P-values between 3.26 ×
10-12 and 1.61 × 10-9. For knock down of LSR with LSR2
the three top ranked functions were related to "cell move-
ment" (P = 2.72 × 10-15), "growth of tumor cell lines" (P
= 4.45 × 10-12), and "cell movement of eukaryotic cells" (P
= 4.54 × 10-12). The same tendency was found at 72 h
where all top-three ranked functions affected by knock-
down of LSR by either LSR siRNA were related to "cellular
movement" (P = 5.60 × 10-15 – 2.46 × 10-9). See Table 2.
Knockdown of LSR and TP53: For knock down of LSR and
TP53 expression in combination the most significant
function affected was related to "renal and urological dis-
order" (P = 3.87 × 10-8). This was even more significant 72
h after transfection (P = 8.15 × 10-9). Genes involved in
that process were EDN1, GADD45A, IL1A, MT2A, PTHLH,
REN,  RRM2B,  SERPINE1,  THBS1,  TGFB1,  UPK2, and
VEGF. Other highly significant functions were "cancer
growth of tumor cell lines" (P = 1.99 × 10-7), and "cellular
growth" and "proliferation" (colony formation of eukary-
otic cells) (P = 5.94 × 10-7). See Table 2.
In conclusion, our in vitro experiment indicated that
knock down of LSR affected genes known to be involved
in cancer and especially cellular movements like invasion,
migration and motility.
Verification of the invasive potential of LSR knockdown
Using a matrigel assay we measured the motility and inva-
sion capacity after knockdown of LSR or TP53 to investi-
gate the in silico predicted functional role of LSR. The
SW780 bladder cancer cell line was transfected with siR-
NAs against LSR (LSR1), TP53 and LSR1+TP53. A mock
siRNA was used as control. The experiment showed that
24 h after transfection, the invasion capacity was signifi-
cantly elevated 3-fold in LSR1 knock-down cells (P =
0.0194) and 2.7-fold in TP53 knock-down cells (P =
0.0203) compared to mock transfected cells (Figure 7).
After 48 h cell motility was elevated 3.5-fold in LSR1
knock down cells (P = 0.0044) and 4.7-fold in TP53
knock-down cells (P = 0.0020) compared to mock trans-
fected cells (Figure 7). There was no significant effect on
motility 24 h after transfection, and no effect on invasion
48 h after transfection. There was no significant effect of
knockdown with siRNAs against LSR and TP53 in combi-
nation.
Measurement of cell viability after knockdown of LSR and 
TP53
Since our "global functional analysis" showed that knock-
down of TP53 transcripts influenced genes involved in cell
death and cell survival we conducted a viability assay to
measure if there were any difference in number of viable
cells. Further, we wanted to see, if the invasion capacity of
LSR knock down cells was due to difference in viability.
We used an assay based on MTT, which is cleaved by via-
ble cells. SW780 cells were transfected in quadruplicate
with siRNAs against mock, LSR, TP53 and TP53+LSR.
However, there was no significant viability difference
between any of the knockdowns and the mock transfected
cells (Additional File 6). Consequently, the invasive
capacity upon LSR knockdown was not caused by a differ-
ence in number of viable cell.
Cellular movement network using cell line and tumor 
derived expression data
Since elevated invasion potential seemed to be an impor-
tant functional consequence of LSR knockdown, we con-
structed a "cellular movement" network. 64 genes, which
were differentially expressed upon knockdown of LSR and
which were significantly related to the gene categories cel-
lular movements, invasion and migration with p-values
below 1.0 × 10-10 were selected for network generation. 60
of these could be directly or indirectly connected using
IPA. Then log ratios of mean expression 48 h after knock-
down with LSR1 compared to mean expression after
knockdown with mock siRNA were superimposed (Figure
8A). Further, from the microarray data from the clinical
specimens we calculated mean expression values and logBMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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Table 2: "Global functional analysis" conducted using Ingenuity Pathway Analysis.
Time after transfection siRNA Category Process Annotation Significance
18 h TP53 Cell Death cell death of tumor cell lines 5.96E-09
Organismal Survival survival of mammalia 9.59E-09
Cell Death cell death of lung cancer cell lines 3.72E-08
Organismal Survival survival of mice 9.84E-08
Cellular Growth and Proliferation colony formation of eukaryotic cells 1.48E-07
LSR1 Cancer proliferation of tumor cell lines 3.78E-07
DNA Replication, Recombination, and 
Repair
synthesis of DNA 4.61E-07
Cell Death apoptosis of cell lines 1.67E-06
Cancer cell death of tumor cell lines 1.95E-06
Organismal Survival survival of mammalia 2.29E-06
LSR2 Cancer growth of tumor cell lines 2.11E-07
Cellular Growth and Proliferation growth of cell lines 3.14E-07
Cancer proliferation of tumor cell lines 1.38E-06
Cardiovascular System Development and 
Function
development of blood vessel 1.78E-06
Cellular Growth and Proliferation growth of eukaryotic cells 2.85E-06
TP53+LSR1 Cellular Growth and Proliferation colony formation of eukaryotic cells 5.07E-10
Organismal Survival survival of mammalia 8.79E-09
Cellular Growth and Proliferation colony formation of cell lines 1.11E-08
Cell Death cell death of cell lines 3.66E-08
Cancer colony formation of tumor cell lines 1.11E-07
48 h TP53 Cell-To-Cell Signaling and Interaction activation of eukaryotic cells 1.17E-10
Organismal Survival survival of rodents 1.74E-09
Cellular Growth and Proliferation proliferation of cell lines 1.29E-08
Cellular Growth and Proliferation growth of central nervous system cells 1.76E-08
Cellular Growth and Proliferation colony formation of cells 3.72E-08
LSR1 Cellular Movement cell movement 3.26E-12
Cellular Movement invasion of eukaryotic cells 2.31E-11
Cellular Movement invasion of cell lines 1.61E-09
Cellular Movement cell movement of cell lines 3.84E-09
Cellular Movement cell movement of endothelial cells 4.24E-09
LSR2 Cellular Movement cell movement 2.72E-15
Cellular Growth and Proliferation growth of tumor cell lines 4.45E-12
Cellular Movement cell movement of eukaryotic cells 4.54E-12
Cell-To-Cell Signaling and Interaction adhesion of cells 4.78E-12
Cellular Movement cell movement of cell lines 7.54E-12
TP53+LSR1 Renal and Urological Disease renal and urological disorder of rodents 3.87E-08
Renal and Urological Disease renal and urological disorder of rats 1.05E-07
Cancer growth of tumor cell lines 1.99E-07
Cellular Growth and Proliferation colony formation of eukaryotic cells 5.94E-07
Cellular Growth and Proliferation colony formation of cell lines 1.18E-06
72 h TP53 Tissue Development development of tissue 5.91E-08
Tissue Development angiogenesis of chorioallantoic membrane 8.76E-08
Renal and Urological Disease renal and urological disorder of rodents 1.01E-07
Cancer angiogenesis of tumor 1.82E-07
Cellular Movement cell movement 1.99E-07
LSR1 Cellular Movement cell movement 8.99E-11
Cellular Movement migration of eukaryotic cells 2.41E-09
Cellular Movement cell movement of eukaryotic cells 2.46E-09
Cellular Movement cell movement of cell lines 5.27E-09
Cellular Movement migration of tumor cell lines 1.72E-08
LSR2 Cellular Movement cell movement 5.60E-15
Cellular Movement cell movement of eukaryotic cells 2.46E-13
Cellular Movement migration of eukaryotic cells 7.57E-13
Cellular Growth and Proliferation growth of tumor cell lines 5.66E-12
Tissue Development formation of tissue 8.77E-12BMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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ratios between tumor and normal urothelium samples,
for the same gene set. These data were superimposed the
same cell movement network (Figure 8B). The correlation
between the gene expression for the two dataset was mar-
ginally significant (Kendall's tau b, one-sided p-value =
0.0526). However, the complexity of the clinical samples
makes this an interesting finding.
Discussion
We investigated the functional role of LSR in vitro by tran-
sient transfection of LSR and TP53 siRNAs into a bladder
cancer cell line (SW780) followed by microarray measure-
ments of gene expression. We used Ingenuity Pathway
Analysis to investigate the relationship among differen-
tially expressed genes upon knockdown and thereby, to
TP53+LSR1 Cellular Movement migration of eukaryotic cells 4.19E-10
Cellular Movement cell movement 8.74E-10
Cellular Movement cell movement of eukaryotic cells 1.57E-09
Cancer angiogenesis of tumor 6.86E-09
Renal and Urological Disease renal and urological disorder of rodents 8.15E-09
The list includes the annotation of the differentially expressed genes upon knockdown. The likelihood that the association between a set of 
differentially expressed genes and a given function was due to chance was calculated using the right-tailed Fisher's exact test. The biological 
functions or processes annotated to affected genes are listed according to their significance.
Table 2: "Global functional analysis" conducted using Ingenuity Pathway Analysis. (Continued)
Cell invasion assay Figure 7
Cell invasion assay. Cells were transfected with siRNAs (Mock, LSR1, TP53, LSR1+TP53) and were allowed to grow for 24 
h or 48 h in control inserts (three samples per transfection) or in matrigel matrix inserts (three samples per transfection). The 
mean number of cells passing the inserts was calculated. Error bars indicate +/- one standard error. Asterisks (*) indicate trans-
fections where the number of cells passing the membrane was significantly different from the mock transfected cells.BMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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Cellular movement and invasion network Figure 8
Cellular movement and invasion network. A; log ratios of mean expression 48 h after knockdown with LSR1 compared 
to mean expression 48 h after knockdown with mock siRNA were overlaid. B; microarray data from 87 bladder tumors and 9 
normal urothelium samples superimposed the cell movement network. Yellow represents up-regulated genes and blue repre-
sents down-regulated genes. Genes not fulfilling the cut-off criteria are not colored.BMC Medical Genomics 2008, 1:31 http://www.biomedcentral.com/1755-8794/1/31
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generate hypotheses and to suggest directions for further
phenotypic analyses. We identified six gene networks con-
taining genes mainly related to the functional categories
"cancer", "cell death", and "cellular movement". Further,
by investigating the entire dataset, we determined that
genes annotated to the functional category "cellular
movement", including "invasion" and "cell motility",
were highly significantly overrepresented among the dif-
ferentially expressed genes after LSR knockdown. We
investigated the role of these genes in a phenotypic
matrigel assay, which showed that the invasion capacity
was significantly elevated 24 h after transfection with
LSR1 or TP53 siRNAs compared to mock transfected cells,
while the motility capacity was significantly elevated 48 h
after transfection with LSR1 or TP53. The motility and
invasion capacity was controlled for cell viability. These
results indicate that in the urinary bladder LSR plays a role
in cancer development.
The role of LSR has been thoroughly investigated in
humans, rats and mice [12-15,17,26]. LSR is mainly
expressed in liver membranes [13,15,17] and is believed
to mediate clearance of chylomicrons after activations of
free fatty acids [13,14]. However, other functions may
exist, since LSR is also expressed in other tissues [20,27-
29]. LSR expression has been shown in tumor tissue like
ovarian cancer, where LSR was one of thirty genes identi-
fied as a potential tumor marker [29].
A relationship between LSR, transforming growth-factor
β1 (TGF-β1) and Smad4 has been investigated in relation
to cell movements measured by a wound closure assay
[20]. TGF-β induced signalling can be induced in a Smad4
dependent and independent way. Briefly, the experiment
showed that in presence of Smad4, TGF-β1 stimulation
depressed LSR expression and induced cell movements.
Upon TGF-β1 stimulation in Smad4 knocked down cells,
LSR was not reduced and migration was delayed. TGFB1
has also been associated with cell migration [30].
In our in vitro experiment we found that TGF-β1 was
upregulated more than 2-fold after knockdown of LSR
(Figure 8A). Similar, we saw that TGF-β1 expression was
upregulated in vivo. Further, our invasion assay showed
that the invasion and migration capacity was elevated
when LSR was downregulated, consistent with the find-
ings by Jazag et al. These results suggest that TGF-β1
expression can be regulated by the LSR level. Smad4 was
not differentially expressed and was not included in the
analysis.
The data document that it is quite useful to conduct time-
course microarray studies and to use in-silico data mining,
such as network and functional network analysis, to
understand the effect of single molecules. In the present
case we would not have identified the invasion and motil-
ity effect of LSR had it not been suggested by the pathway
analysis.
In an effort to handle possible off-target effects we
included two different siRNAs against LSR. Both siRNAs
demonstrated a comparable knockdown effect of LSR. Six-
teen genes were constitutively regulated over time by both
LSR siRNAs. Among these were CYR61, which has been
shown to be overexpressed and associated with advanced
stages of breast cancer [31], and EGR1, which is believed
to be a direct regulator of tumor suppressors like TGFB1,
TP53 and PTEN [32]. EGR1 was upregulated upon knock-
down of LSR in vitro and upregulated when comparing
tumor samples with normal urothelium samples, though
not significantly. Finally, the "local network analysis" and
the "global functional analysis" conducted in IPA showed
overall the same findings. Therefore, we believe that our
LSR siRNAs mainly target the same LSR transcript and that
possible off-target effects are minimal.
We included knockdown of TP53 for two reasons: First,
LSR was previously identified as a potential primary target
of TP53 [19]. In our experiment we could not see any
effect on LSR transcription after TP53 knockdown and
vice versa. Secondly, we included knockdown of TP53 as
a control model in our in silico investigations. Both the
"local network analysis" and the "global functional anal-
ysis" showed that genes affected by TP53 knockdown
could be related to cancer and cell death.
Conclusion
LSR may be involved in both invasion, and cellular move-
ment in bladder cancer. Future research will document
whether LSR-like molecules could be used therapeutically
in bladder cancer treatment.
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